Clinical

Videos

The MD Anderson expert discussed the main takeaway from the data published during the virtual AACR Annual Meeting, while looking forward to what comes next with these genetic drivers.

Michael Kim, MD, Discusses Study on Mutant p53 and Oncogenic KRAS in Pancreatic Cancer

Articles

According to investigators, study findings could help guide treatment decisions and future research, as well as suggest new biomarkers for exploration.

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer 

The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.

Phase 3 Study Explores Pamrevlumab for Unresectable LAPC 

Per a planned interim superiority analysis conducted by an independent data monitoring committee, a trial of Eryaspace will continue without modification with final results anticipated later this year.

Phase 3 TRYbeCA-1 Trial in Second-Line Pancreatic Cancer Will Continue to Final Analysis

Sohal spoke with CancerNetwork® regarding recent clinical data investigating 2 common pancreatic cancer treatment regimens: FOLFIRINOX and gemcitabine/nab-paclitaxel.

Davendra Sohal, MD, MPH, Discusses Major Takeaways From Key Research in Pancreatic Cancer

A study found a number of factors associated with increased recurrence risk for patients with locally advanced pancreatic neuroendocrine tumors following surgical resection, including sex, lymph node metastases, and resection of other organs with tumor involvement.

Lymph Node Metastases, Additional Organ Resection Associated With Increased Recurrence Risk for PNETs

The FDA placed a clinical hold on patient enrollment and dosing for the ongoing phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer.

FDA Places Clinical Hold on Phase 1/2 Trial Evaluating BPX-601 for Metastatic Pancreatic, Prostate Cancer

Study results suggested that maintenance olaparib (Lynparza) is potentially cost-effective compared with placebo for patients with metastatic pancreatic cancer and a germline BRCA mutation.

Maintenance Olaparib May Be Cost-Effective for BRCA-Mutated Metastatic Pancreatic Cancer

Podcasts

The latest installment of “Oncology Peer Review On-The-Go” dissects original research published in the journal ONCOLOGY regarding potential barriers to clinical trial enrollment for patients with pancreatic cancer.

Oncology Peer Review On-The-Go: Barriers to Pancreatic Cancer Clinical Trial Enrollment

This 20-year analysis suggested that weight loss surgery significantly decreases the risk of developing pancreatic cancer in individuals who are obese with diabetes.

Pancreatic Cancer | Topics